The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence found in previous ...

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...

MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...

Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

WINREVAIR is currently approved in the U.S. and 38 countries based on the results from the Phase 3 STELLAR trial. *World Health Organization **Dr. McLaughlin is a member of the adult sotatercept ...

The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of the disease. This decision is based on strong efficacy data from ...

WINREVAIR is currently approved in the U.S. and 38 countries based on the results from the Phase 3 STELLAR trial. *World Health Organization **Dr. McLaughlin is a member of the adult sotatercept ...